Conversion to Everolimus in Kidney Transplant Recipients With Decreased Renal Function

Transplantation Proceedings

Volumn 41, Issue 6, 2009, Pages 2134-2136

  Inza, A ^a   Balda, S ^b   Alvarez E ^a   Zarraga S ^a   Gainza F J ^a   Lampreabe, I ^a  

^a HOSPITAL DE CRUCES   (Spain)

^b HOSPITAL SAN PEDRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AGED; ANEMIA; ARTICLE; CASE REPORT; CHRONIC ALLOGRAFT NEPHROPATHY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; NEPHROTIC SYNDROME; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEINURIA; RECIPIENT; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; CREATININE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; PREDNISONE; SIROLIMUS; SURVIVAL RATE; TIME FACTORS; YOUNG ADULT;

EID: 68949218838     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.05.013     Document Type: Article

References (9)

1. Dominguez J., Mahalati K., Kiberd B., et al. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantion 72 (2001) 1464
2. Lutz J., Zou H., Liu S., et al. Apoptosis and treatment of chronic allograft nephropathy with everolimus. Transplantation 76 (2003) 50
3. Nankivell B.J., Borrows R.J., Chir B., et al. The natural history of chronic allograft nephropathy. N Engl J Med 349 (2003) 2326
4. Ruiz J.C., Campistol J.M., Sánchez-Fructuoso A., et al. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dialysis Transplant 21 (2006) 3252
5. Sánchez Fructuoso A., Ruiz San Millán J.C., Calvo N., et al. Evaluation of efficacy and safety of the conversion from a calcineurin inhibitor to an everolimus-based therapy in maintenance renal transplant patients. Transplant Proc (2007)
6. Letavernier E., Peraldi M.N., Pariente A., et al. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 80 (2005) 1198
7. Ruiz J.C., Diekmann F., Campistol J.M., et al. Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: a multicenter study. Transplant Proc 37 (2005) 3833
8. Bumbea V., Kamar N., Ribes D., et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dialysis Transplant 20 (2005) 2517
9. Sánchez Fructuoso A., Calvo N., Moreno M.A., et al. Study of anemia late introduction of everolimus in the immunosuppressive treatment of renal transplant patients. Transplant Proc 39 (2007) 2242